Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors

LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/regenxbio-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

REGENXBIO is a clinical-stage biotechnology company that provides gene therapies that deliver functional genes to cells with genetic defects.  REGENXBIO is developing product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome.

The REGENXBIO class action lawsuit alleges that defendants throughout the Class Period disseminated false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study.

The REGENXBIO investor class action lawsuit alleges that on January 28, 2026. REGENXBIO announced that the U.S. Food & Drug Administration placed a clinical hold on its investigational gene therapy RGX-111.  In pertinent part, defendants allegedly announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study.  On this news, the price of REGENXBIO fell nearly 18%, according to the complaint.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com 

Attorney Advertising

You May Also Be Interested In

• New Anglia University Responds to increasing demand from UK students, reinforces its commitment to providing a UK-focused medical education pathway
• New York Supreme Court Awards Newsweek Nearly $11 Million Judgment Against Former Owner IBT Media Inc.
• Acrisure Introduces Asero Insurance Services, Combining Specialty MGAs under a Unified Brand